133 related articles for article (PubMed ID: 21750560)
1. Mutations galore in myeloproliferative neoplasms: would the real Spartacus please stand up?
Tefferi A
Leukemia; 2011 Jul; 25(7):1059-63. PubMed ID: 21750560
[No Abstract] [Full Text] [Related]
2. [Not Available].
Mosca M; Vertenoeil G; Toppaldoddi KR; Plo I; Vainchenker W
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S16-28. PubMed ID: 27494969
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders.
Jost E; do O N; Dahl E; Maintz CE; Jousten P; Habets L; Wilop S; Herman JG; Osieka R; Galm O
Leukemia; 2007 Mar; 21(3):505-10. PubMed ID: 17230231
[TBL] [Abstract][Full Text] [Related]
4. [Application of novel tyrosine-kinase inhibitors for the treatment of leukemia and Ph-negative myeloproliferative neoplasms].
Kirito K
Rinsho Ketsueki; 2011 Jul; 52(7):460-8. PubMed ID: 21821977
[No Abstract] [Full Text] [Related]
5. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
[TBL] [Abstract][Full Text] [Related]
6. Acquisition of genomic events leading to lymphoblastic transformation in a rare case of myeloproliferative neoplasm with BCR-JAK2 fusion transcript.
Duployez N; Nibourel O; Ducourneau B; Grardel N; Boyer T; Bories C; Darre S; Coiteux V; Berthon C; Preudhomme C; Roche-Lestienne C
Eur J Haematol; 2016 Oct; 97(4):399-402. PubMed ID: 26935241
[TBL] [Abstract][Full Text] [Related]
7. DNMT3A mutations in myeloproliferative neoplasms.
Stegelmann F; Bullinger L; Schlenk RF; Paschka P; Griesshammer M; Blersch C; Kuhn S; Schauer S; Döhner H; Döhner K
Leukemia; 2011 Jul; 25(7):1217-9. PubMed ID: 21537334
[No Abstract] [Full Text] [Related]
8. [New mutations in myeloproliferative neoplasms; 2014 update].
Kirito K
Rinsho Ketsueki; 2014 Oct; 55(10):1833-40. PubMed ID: 25297747
[No Abstract] [Full Text] [Related]
9. A new allelic discrimination assay using locked nucleic acid-modified nucleotides (LNA) probes for detection of JAK2 V617F mutation.
Marková J; Průková D; Volková Z; Schwarz J
Leuk Lymphoma; 2007 Mar; 48(3):636-9. PubMed ID: 17454614
[No Abstract] [Full Text] [Related]
10. Guest Editorial: Understanding of MPN and MDS/MPN based on molecular pathogenesis and clinical aspects.
Harada H
Int J Hematol; 2017 Jun; 105(6):709-710. PubMed ID: 28447249
[No Abstract] [Full Text] [Related]
11. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
Pikman Y; Levine RL
Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464
[TBL] [Abstract][Full Text] [Related]
12. What is the role of JAK2(V617F) mutation in leukemic transformation of myeloproliferative neoplasms?
Lopes da Silva R; Ribeiro P; Lourenço A; Santos SC; Santos M; Costa I; de Sousa AB
Lab Hematol; 2011 Mar; 17(1):12-6. PubMed ID: 21421540
[TBL] [Abstract][Full Text] [Related]
13. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
14. Chronic myeloproliferative neoplasm with concurrent BCR-ABL translocation and JAK2 mutation.
Siddiqui NS; Ssiddiqui HS; Qurat-Ul-Ain ; Siddiqui SA
J Coll Physicians Surg Pak; 2010 Jun; 20(6):423. PubMed ID: 20642980
[No Abstract] [Full Text] [Related]
15. JAK-mutant myeloproliferative neoplasms.
Levine RL
Curr Top Microbiol Immunol; 2012; 355():119-33. PubMed ID: 21823028
[TBL] [Abstract][Full Text] [Related]
16. Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.
Pasquier F; Cabagnols X; Secardin L; Plo I; Vainchenker W
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S23-35. PubMed ID: 25486952
[TBL] [Abstract][Full Text] [Related]
17. Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression.
Klampfl T; Harutyunyan A; Berg T; Gisslinger B; Schalling M; Bagienski K; Olcaydu D; Passamonti F; Rumi E; Pietra D; Jäger R; Pieri L; Guglielmelli P; Iacobucci I; Martinelli G; Cazzola M; Vannucchi AM; Gisslinger H; Kralovics R
Blood; 2011 Jul; 118(1):167-76. PubMed ID: 21531982
[TBL] [Abstract][Full Text] [Related]
18. Progression of myeloproliferative neoplasm with BCR::JAK2 fusion to acute leukemia of ambiguous lineage.
Suárez EU; Piris MÁ; Rodríguez-Pinilla SM; García JF; López-Lorenzo JL; Cornago-Navascués J; Salgado-Sánchez R; Castaño-Bonilla T; Mata-Serna R; Alonso-Domínguez JM; Llamas P
Ann Hematol; 2024 May; 103(5):1797-1799. PubMed ID: 38308706
[No Abstract] [Full Text] [Related]
19. [Research advances in the role of JAK2 mutations in acute leukemia].
Zhang HY; Zhai XW
Zhongguo Dang Dai Er Ke Za Zhi; 2015 Jun; 17(6):644-9. PubMed ID: 26108332
[TBL] [Abstract][Full Text] [Related]
20. BCR-ABL-negative chronic myeloid leukemia.
Burgstaller S; Reiter A; Cross NC
Curr Hematol Malig Rep; 2007 May; 2(2):75-82. PubMed ID: 20425354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
